Venture capital firm Third Rock Ventures last week announced that it has put up $45 million to form a new company called Voyager Therapeutics to develop adeno-associated viral vector-enabled treatments for central nervous system disorders.

Although the company's lead program is a gene-replacement therapy for Parkinson's disease, Voyager has also set its sights on using its AAV technology to develop expressed RNAi drugs — an effort that includes a preclinical program in amyotrophic lateral sclerosis, according to a company executive.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.